Condition
Beta Lactam Resistant Bacterial Infection
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 4 (2)
Trial Status
Withdrawn1
Completed1
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03671967Phase 4RecruitingPrimary
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
NCT05355350Phase 4WithdrawnPrimary
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
NCT03752476Unknown
Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria
NCT03655548Completed
Optimization Management Study of Community Urinary Tract Infections Spectrum
Showing all 4 trials